TARS Stock Price, Tarsus Pharmaceuticals Quote, Chart

Market Summary

USD31.98-0.23

Delayedas of 26 Apr 2024, 02:00 pm

-0.71%

TARS Alerts

5 major insider sales recently.

TARS Stock Price

View Fullscreen

TARS RSI Chart

TARS Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-8.11

Price/Sales (Trailing)

44.18

EV/EBITDA

-6.88

Price/Free Cashflow

-9.26

TARS Price/Sales (Trailing)

TARS Profitability

EBT Margin

-544.73%

Return on Equity

-68.99%

Return on Assets

-51.19%

Free Cashflow Yield

-10.8%

TARS Fundamentals

TARS Revenue

Revenue (TTM)

24.9M

Rev. Growth (Yr)

30.76%

Rev. Growth (Qtr)

598.88%

TARS Earnings

Earnings (TTM)

-135.9M

Earnings Growth (Yr)

-208.13%

Earnings Growth (Qtr)

-7.03%

Breaking Down TARS Revenue

52 Week Range

14.3233.11

(Low)(High)

Last 7 days

-2.0%

Last 30 days

-4.9%

Last 90 days

24.8%

Trailing 12 Months

122.9%

How does TARS drawdown profile look like?

TARS Financial Health

Current Ratio

6.93

Debt/Equity

0.15

Debt/Cashflow

-3.94

TARS Investor Care

Shares Dilution (1Y)

24.12%

Diluted EPS (TTM)

-4.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	27.1M	24.9M
2022	49.2M	41.4M	33.6M	25.8M
2021	0	0	0	57.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tarsus Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	wahl bryan	sold	-135,742	30.6	-4,436	general counsel
Mar 18, 2024	azamian bobak r.	sold	-318,699	30.6	-10,415	president/ceo and board chair
Mar 18, 2024	mottiwala aziz	sold	-145,840	30.6	-4,766	chief commercial officer
Mar 18, 2024	neervannan seshadri	sold	-149,297	30.6	-4,879	chief operating officer
Mar 18, 2024	whitfield dianne c.	sold	-132,008	30.6	-4,314	chief human resources officer
Mar 15, 2024	wahl bryan	acquired	-	-	12,038	general counsel
Mar 15, 2024	azamian bobak r.	acquired	-	-	28,274	president/ceo and board chair
Mar 15, 2024	mottiwala aziz	acquired	-	-	12,938	chief commercial officer
Mar 15, 2024	whitfield dianne c.	acquired	-	-	11,711	chief human resources officer
Mar 15, 2024	neervannan seshadri	acquired	-	-	13,245	chief operating officer

Which funds bought or sold TARS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	17.66	472,000	896,000	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	222,935	222,935	-%
Apr 24, 2024	Spire Wealth Management	added	101	3,285	4,835	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-59.99	-14,000	36,000	-%
Apr 23, 2024	Venturi Wealth Management, LLC	unchanged	-	13,862	31,298	-%
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	new	-	218,100	218,100	0.02%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	16.27	964,698	1,852,030	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	21.71	87,798	314,685	-%
Apr 22, 2024	Vivo Capital, LLC	reduced	-68.3	-15,568,400	20,557,700	1.61%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	2.61	3,195,080	6,990,210	0.01%

Are Funds Buying or Selling TARS?

Are funds buying TARS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TARS

No. of Funds

TARS Alerts

5 major insider sales recently.

Unveiling Tarsus Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cormorant asset management, lp	4.83%	1,600,000	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.5%	3,152,341	SC 13G/A
Feb 14, 2024	tang capital partners lp	6.7%	2,204,797	SC 13G/A
Feb 13, 2024	vivo capital ix, llc	2.7%	894,826	SC 13G/A
Feb 09, 2024	morgan stanley	5.9%	1,943,705	SC 13G
Feb 02, 2024	cowen financial products llc	5.77%	1,911,399	SC 13G/A
Feb 02, 2024	timessquare capital management, llc	0%	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	2,515,124	SC 13G
Jan 22, 2024	paradigm biocapital advisors lp	5.8%	1,927,506	SC 13G
May 05, 2023	cowen financial products llc	5.22%	1,398,983	SC 13G

Recent SEC filings of Tarsus Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Apr 11, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Tarsus Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Tarsus Pharmaceuticals Inc News

Latest updates

Tarsus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	598.9%	13,076,000	1,871,000	10,000,000	-	15,277,000	7,807,500	338,000	1,240,000	22,017,000	33,432,000
Costs and Expenses	-100.0%	-	42,806,000	-	22,906,000	20,501,000	20,060,000	-	16,945,000	-	-
Operating Expenses	-	-	-	-	-	20,501,000	20,060,000	14,786,000	16,945,000	14,735,000	22,718,000
S&GA Expenses	41.8%	43,005,000	30,324,000	14,633,000	11,994,000	10,376,000	7,946,000	6,772,000	6,671,000	6,794,000	5,160,000
R&D Expenses	9.9%	13,305,000	12,105,000	10,028,000	10,912,000	9,603,000	12,081,000	8,038,000	10,209,000	7,204,000	16,261,000
EBITDA Margin	-Infinity%	-5.29	-	-2.31	-	-	-	-	-	-	-
Interest Expenses	15.3%	989,000	858,000	699,000	633,000	544,000	316,000	-	-	-	-
Income Taxes	-	-	-	-	-5,000	-	1,000	54,000	-341,000	29,000	313,000
EBT Margin	-Infinity%	-5.45	-	-2.41	-0.41	-0.33	-0.28	-0.24	-	-	-
Net Income	-7.0%	-41,902,000	-39,148,000	-13,599,000	-22,511,000	-5,743,000	-20,238,000	-14,851,000	-15,697,000	6,345,000	10,376,000
Net Income Margin	-37.4%	-5.45	-3.96	-2.41	-1.88	-1.36	-0.90	-0.24	-	-	-
Free Cashflow	-20.2%	-39,335,000	-32,737,000	-11,001,000	-18,707,000	-4,381,000	-15,447,000	-12,395,000	6,991,000	20,535,000	-11,969,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-1.1%	265	268	189	211	228	236	253	181	179	190	203	194	172	92.00	58.00
Current Assets	-1.2%	256	259	183	209	225	234	250	179	176	187	201	191	171	89.00	58.00
Cash Equivalents	-0.8%	225	227	107	66.00	72.00	169	245	175	171	184	177	156	168	86.00	58.00
Inventory	20613.3%	3.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-9.0%	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	0.00
Liabilities	25.3%	69.00	55.00	41.00	38.00	35.00	34.00	31.00	32.00	12.00	11.00	11.00	11.00	6.00	7.00	1.00
Current Liabilities	58.9%	37.00	23.00	15.00	13.00	15.00	14.00	12.00	13.00	11.00	10.00	10.00	10.00	5.00	6.00	1.00
Long Term Debt	0.4%	30.00	30.00	25.00	25.00	19.00	19.00	19.00	19.00	-	-	-	-	-	-	-
LT Debt, Non Current	0.4%	30.00	30.00	25.00	25.00	19.00	19.00	19.00	19.00	-	-	-	-	-	-	-
Shareholder's Equity	-7.8%	197	214	148	173	193	203	222	149	167	179	192	183	166	-	-
Retained Earnings	-20.7%	-244	-202	-163	-132	-108	-95.16	-72.65	-66.91	-46.67	-31.80	-16.12	-22.47	-32.80	-21.38	-6.03
Additional Paid-In Capital	6.1%	442	416	311	306	302	298	294	216	213	211	209	206	199	4.00	0.00
Shares Outstanding	3.3%	34.00	33.00	27.00	27.00	27.00	24.00	23.00	21.00	21.00	21.00	20.00	20.00	-	-	-
Float	-	-	-	460	-	-	-	181	-	-	-	484	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-21.5%	-39,335	-32,362	-23,826	-21,970	-10,874	-18,611	-4,259	-15,286	-12,121	7,112	20,551	-11,794	-10,013	-6,572	-2,557	-1,996	-	-
Share Based Compensation	4.4%	5,482	5,250	5,192	3,906	3,671	3,583	3,532	2,674	2,179	2,119	2,794	1,363	438	224	173	4.00	-	-
Cashflow From Investing	-62.3%	17,850	47,368	64,092	11,294	-87,219	-57,127	-122	-161	-274	-121	-16.00	-175	50.00	-135	-335	-36.00	-	-
Cashflow From Financing	-81.2%	19,760	104,893	510	5,013	264	-136	74,734	19,125	-74.00	75.00	1.00	19.00	91,763	39,901	134	-27.00	-	-

TARS Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 17,447	$ 25,816
Operating expenses:
Research and development	50,312	42,624
Selling, general and administrative	108,700	44,949
Total operating expenses	160,605	88,528
Loss from operations	(143,158)	(62,712)
Other income (expense):
Interest income	10,337	3,499
Interest expense	(3,346)	(2,199)
Other (expense) income, net	(102)	86
Unrealized gain (loss) on equity investments	259	(268)
Change in fair value of equity warrants issued by licensee	117	(501)
Total other income, net	7,265	617
Loss before income taxes	(135,893)	(62,095)
Benefit from income taxes	0	4
Net loss	(135,893)	(62,091)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities and cash equivalents	72	(74)
Comprehensive loss	$ (135,821)	$ (62,165)
Net loss per share, basic (in USD per share)	$ (4.62)	$ (2.52)
Net loss per share, diluted (in USD per share)	$ (4.62)	$ (2.52)
Weighted-average common shares outstanding, basic (shares)	29,383,276	24,619,700
Weighted-average common shares outstanding, diluted (shares)	29,383,276	24,619,700
Product sales, net
Revenues:
Total revenues	$ 14,729	$ 0
Operating expenses:
Cost of sales	1,593	0
License fees and collaboration revenue
Revenues:
Total revenues	2,718	25,816
Operating expenses:
Cost of sales	$ 0	$ 955

TARS Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 224,947,000	$ 71,660,000
Marketable securities	2,495,000	145,366,000
Accounts receivable, net	16,621,000	0
Inventory	3,107,000	0
Other receivables	1,093,000	3,582,000
Prepaid expenses	7,868,000	4,767,000
Total current assets	256,131,000	225,375,000
Property and equipment, net	1,468,000	957,000
Intangible assets, net	3,867,000	0
Operating lease right-of-use assets	1,880,000	575,000
Long-term investments	631,000	371,000
Other assets	1,514,000	585,000
Total assets	265,491,000	227,863,000
Current liabilities:
Accounts payable and other accrued liabilities	23,691,000	9,910,000
Accrued payroll and benefits	13,245,000	5,519,000
Total current liabilities	36,936,000	15,429,000
Term loan, net	29,819,000	19,434,000
Other long-term liabilities	1,748,000	100,000
Total liabilities	68,503,000	34,963,000
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 34,211,190 shares issued and outstanding at December 31, 2023; 26,727,458 shares issued and outstanding at December 31, 2022	5,000	5,000
Additional paid-in capital	441,641,000	301,732,000
Accumulated other comprehensive loss	(2,000)	(74,000)
Accumulated deficit	(244,656,000)	(108,763,000)
Total stockholders’ equity	196,988,000	192,900,000
Total liabilities and stockholders’ equity	$ 265,491,000	$ 227,863,000

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

CEO	Dr. Bobak R. Azamian M.D.
WEBSITE	tarsusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	87

Tarsus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Tarsus Pharmaceuticals Inc? What does TARS stand for in stocks?

TARS is the stock ticker symbol of Tarsus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tarsus Pharmaceuticals Inc (TARS)?

As of Thu Apr 25 2024, market cap of Tarsus Pharmaceuticals Inc is 1.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers. The fair value of Tarsus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tarsus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TARS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tarsus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TARS is over valued or under valued. Whether Tarsus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tarsus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARS.

What is Tarsus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, TARS's PE ratio (Price to Earnings) is -8.11 and Price to Sales (PS) ratio is 44.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARS PE ratio will change depending on the future growth rate expectations of investors.